WallStSmart

Day One Biopharmaceuticals Inc (DAWN)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Day One Biopharmaceuticals Inc generates 21218% more annual revenue ($158.18M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -67.8%. DAWN earns a higher WallStSmart Score of 30/100 (F).

DAWN

Avoid

30

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 5.0

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DAWN1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
83.9%10/10

Revenue surging 83.9% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

DAWN4 concerns · Avg: 2.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-22.7%2/10

ROE of -22.7% — below average capital efficiency

Free Cash FlowQuality
$-17.65M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-67.8%1/10

Currently unprofitable

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DAWN

The strongest argument for DAWN centers on Revenue Growth. Revenue growth of 83.9% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : DAWN

The primary concerns for DAWN are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

DAWN profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

DAWN is growing revenue faster at 83.9% — sustainability is the question.

DAWN generates stronger free cash flow (-18M), providing more financial flexibility.

Bottom Line

DAWN scores higher overall (30/100 vs 24/100) and 83.9% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Day One Biopharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and markets targeted therapies for patients with genetically defined cancers. The company is headquartered in South San Francisco, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?